Skip to content

A Prospective Multicenter Real-World Registry of Quantitative Flow Ratio-Guided Coronary REvascularization and QuAlity evaLuation

A Prospective Multicenter Real-World Registry of Quantitative Flow Ratio-Guided Coronary REvascularization and QuAlity evaLuation

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07766434
Acronym
QFR-REAL
Enrollment
10000
Registered
2026-08-14
Start date
2026-08-01
Completion date
2029-07-01
Last updated
2026-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Quantitative Coronary Angiography, Quantitative Flow Ratio, Percutaneous Coronary Intervention, Myocardial Ischaemia

Brief summary

This prospective, multicenter observational registry aims to establish a QFR-based quality control standard system for coronary revascularization in patients with coronary artery disease. The study will enroll over 10,000 patients with visually estimated at least one main branch coronary stenosis ≥50% from more than 50 centers across China (covering provincial, municipal, and county-level hospitals). Coronary angiographic images and intracoronary imaging (if available) will be collected and retrospectively analyzed by an independent core laboratory. The primary endpoint is QFR acquisition accessibility, defined as the mean of QFR usage proportion across centers.

Detailed description

This is a prospective, multicenter, observational registry study conducted at more than 50 centers across China. Patients with coronary angiography showing visually estimated at least one main branch stenosis ≥50% who undergo PCI or receive conservative treatment for acute coronary syndrome (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction \>4 weeks after onset) or chronic coronary syndrome (including stable angina and asymptomatic myocardial ischemia) will be consecutively enrolled. Coronary angiographic images will be submitted to an independent core laboratory for retrospective QFR analysis. The study will establish a QFR-based quality control standard system for coronary revascularization. Prespecified subgroup analyses will be performed to assess the concordance rates, overtreatment, and undertreatment rates between clinical decisions and offline core laboratory QFR, and to explore heterogeneity across hospital levels, clinical presentations, disease complexity, target vessel, operator annual PCI volume, QFR image analyzability, and lesion morphology. Other prespecified subgroups will be analyzed for the primary and secondary endpoints, including age, sex, diabetes, smoking status, acute coronary syndrome, body mass index, left ventricular ejection fraction, lesion location, length and reference vessel diameter, stenosis severity, multivessel disease, calcified lesion, bifurcation, tandem and bending/tortuous lesion, QFR gray zone (0.75-0.85), QFR based functional and residual functional SYNTAX score, residual QFR, center experience for invasive physiology, and learning experience with QFR.

Interventions

None listed

Sponsors

China National Center for Cardiovascular Diseases
Lead SponsorOTHER_GOV
Guangdong Provincial People's Hospital
CollaboratorOTHER
First Affiliated Hospital Xi'an Jiaotong University
CollaboratorOTHER
Sir Run Run Shaw Hospital
CollaboratorOTHER
Fuwai Huazhong Cardiovascular Hospital
CollaboratorUNKNOWN
Fuwai Yunnan Cardiovascular Hospital
CollaboratorOTHER
Second Hospital of Jilin University
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years * Coronary angiography showing visually estimated at least one main branch coronary stenosis ≥50% in patients with acute coronary syndrome (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction \>4 weeks after onset) or chronic coronary syndrome (including stable angina and asymptomatic myocardial ischemia) who undergo PCI or receive conservative treatment * Ability to understand the study design and provide written informed consent

Exclusion criteria

* ST-segment elevation myocardial infarction within 4 weeks of onset * History of coronary artery bypass grafting (CABG) or planned CABG within 6 months * Inability to undergo coronary angiography * Non-cardiac cause with expected survival \<1 year * Other conditions that may interfere with follow-up (e.g., dementia, substance abuse including drug addiction and other drug dependencies) * Refusal to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
QFR Adoption RateAt enrollment (baseline)Defined as the mean across participating centers of the proportion of patients undergoing QFR assessment among eligible patients at each center.

Secondary

MeasureTime frameDescription
MACE6 month, 1 year, 3 years, and 5 yearsA composite of all-cause mortality, any myocardial infarction and any ischemia-driven revascularization
Death6 months, 1 year, 3 years, and 5 yearsCardiovascular, non-cardiovascular and undetermined death
MI6 months, 1 year, 3 years, and 5 yearsTarget vessel related and non-target vessel related MI
Target vessel revascularization (TVR)6 months, 1 year, 3 years, and 5 yearsThe ischemia driven and non-ischemia driven TVR
Any coronary artery revascularization6 months, 1 year, 3 years, and 5 yearsThe ischemia driven and non-ischemia driven Revascularization
Definite or probable stent thrombosis6 months, 1 year, 3 years, and 5 yearsDefinite and probable stent thrombosis during acute, sub-acute, late, and very late phase according to the Academic Research Consortium (ARC)-2

Countries

China

Contacts

CONTACTJie Qian, PhD
qianjfw@163.com010-88396089

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 15, 2026